Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

NCT01928537 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndromes
Refractory Anemia With Excess Blasts
Chronic Myelomonocytic Leukemia
Cytopenia

Interventions

DRUG: rigosertib sodium

Sponsor

Traws Pharma, Inc.